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Abstract
BACKGROUND: The aim of this study was to evaluate the feasibility and accuracy of sentinel lymph node (SLN) detection 
using preoperative lymphoscintigraphy and intra-operative gamma probe/blue dye for endometrial cancer patients.
MATERIAL AND METHODS: Twenty four consecutive patients with endometrial cancer were recruited. All patients underwent 
lymphatic mapping and sentinel node biopsy using combined intracervical radiotracer and blue dye injections. Pelvic lymph 
node dissection was performed for all patients. Para-aortic lymphadenectomy was done in high risk patients. All SLNs were 
examined by frozen section and Hematoxylin and Eosin (H&E) permanent sections.
RESULTS: Pre-operative lymphoscintigraphy showed at least one SLN in 21/24 patients. Intra-operatively, at least one SLN 
could be harvested by gamma probe and/or blue dye methods. A total of 95 SLNs were detected. Four SLNs were detected 
only by blue dye, 42 only by radiotracer, and 49 were hot/blue. Median number of SLN per patient was 3. Three patients had 
positive pelvic lymph nodes. All of them had positive SLN (no false negative case). Frozen section could identify SLN involve-
ment in two of three patients with positive pathology. 
CONCLUSION: Lymphatic mapping and sentinel node biopsy is feasible and accurate in endometrial cancer patients using 
combined radiotracer and blue dye methods. Frozen section accuracy was lower and underscores the importance of expert 
pathologists for SLN mapping technique.
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Background
Gynecological cancers are important female life-threatening 
malignancies among which endometrial cancer is the most com-
mon in most areas of the world [1]. The primary surgical procedure 
for endometrial cancer patients include total hysterectomy with 
bilateral salpingo-oophorectomy [2]. A controversial issue in the 
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management of the endometrial cancer is whether or not to perform 
systematic pelvic lymphadenectomy and paraaortic lymphadenec-
tomy because of the inability to predict those patients who would 
benefit from lymph node dissection [3–5].
Complete pelvic and paraaortic lymphadenectomy may cause 
severe surgical complications which can considerably affect the 
quality of life of the patients [6]. In order to avoid lymphadenec-
tomy, the sentinel lymph node (SLN) concept has been applied to 
the treatment of several solid tumors [7–9]. This concept has also 
been used in endometrial cancer patients since 1996 and many 
groups reported their experience on this technique thus far [10, 11].
The aim of this study was to evaluate the feasibility and accuracy 
of sentinel lymph node detection using preoperative lymphoscintig-
raphy and intra operative gamma probe/blue dye for endometrial 
cancer patients.
Material and methods
From October 2010 to December 2012, consecutive pa-
tients who had a histologically verified endometrial cancer and early 
stage on pre-operative evaluation underwent lymphatic mapping 
and were enrolled into the study. The study was approved by the 
ethics committee of Mashhad University of Medical Sciences under 
the approval number of 89 706 and all patients were required to sign 
an informed consent. The procedures followed were in accordance 
with the Helsinki Declaration.
Preoperative lymphoscintigraphy was obtained following intrac-
ervical injection (at 3 and 9 o’clock positions) of 2 mCi radiotracer 
(Tc-99m-Antimony Sulfide Colloid in 15 patients and Tc-99m-Phytate 
in 9 patients) in 0.4 mL volume divided to two aliquots. Imaging 
was done 15 minutes post-radiotracer injection (ANT-POST and 
Lat views 5 min/view using low energy high resolution collimator 
and Tc-99m photopeak) with a dual head variable angle gamma 
camera (E.CAM, Siemens) [12, 13].
The day after radiotracer injection (18–24 hours post injection), 
the patients underwent surgical operation. In all patients, methylene 
blue dye was injected directly into the cervix in the operating room. 
The injection was performed just before incising the skin. Two 2 ml 
syringes, each containing methylene blue dye (0.5 ml) were used 
for each patient. Injection sites were the same as the radiotracer.
Detection of SLNs was accomplished through direct visualization 
of blue colored lymphatics and nodes, and/or by detection of radioac-
tivity, using a handheld gamma probe (EUROPROBE, France). All hot 
and/or blue nodes were harvested and sent for intra-operative frozen 
section evaluation. The surgeon then proceeded to do a complete 
pelvic lymphadenectomy in all cases regardless of the SLNs frozen 
section results. Para-aortic lymphadenectomy was done only in 
selected cases (clear cell, serous or adenosquamous types, grade 
2 or 3 endometrioid carcinomas). Bilateral lymphadenectomy was fol-
lowed by total hysterectomy and bilateral salpingo-oophorectomy.
Results
Overall, 24 patients were included in the study. Table 1 shows the 
characteristics of the included patients. All patients were injected 
with both radiotracer and blue dye. However, gamma probe was de-
fective during surgery of one patient and only blue dye technique 
was used for this specific patient.
Preoperative lymphoscintigraphy visualized SLN in 21/24 
patients (Figure 1). Intraoperative localization of the SLN was pos-
sible in all 24 patients (100% surgical detection rate). A total of 95 
SLNs were identified (median SLNs per patient of 3). SLNs were 
detected bilaterally in 16 and unilaterally in 8 patients. The anatomic 
distribution of the SLNs is shown in Table 2. No para-aortic SLN 
was detected intra-operatively. Four SLNs were detected only by 
blue dye, 42 only by radiotracer, and 49 were hot/blue. 
Pelvic lymph nodes were pathologically involved in 3 patients. 
SLNs of these three patients were also positive on pathological 
examination (2 were positive by frozen section and 1 by H&E 
examination). The false negative rate for H&E was 0% and for 
frozen section examination was 33%. Two of these patients had 
pathologically involved non-SLN too. 
Discussion
Our results revealed a 100% detection rate, suggesting that SLN 
detection is feasible using intra-operative and preoperative cervical 
injections for endometrial cancer. Furthermore, SLN detection was not 
related to histological type or grade of endometrial carcinoma. Pre-
operative lymphoscintigraphy with cervical injection of radiotracer 
visualized SLN in 21/24 patients. More importantly, intraoperative 
localization of the SLN was possible in all patients even those with 
lymphoscintigraphy detection failure. In another study, Abu-Rustum et 
al. reported that preoperative lymphoscintigraphy visualized SLN in 30 
Table 1. Characteristics of the study population
Age (years) 56 (33–86)
BMI [kg/m2] 32 (25–35)
   Histology
   Endometrioid 20
   Papillary serous 3
   Clear cell 1
Grade
   I 9
   II 7
   III 4
Stage
   I 14
   II 4
   III 5
   IV 1
Lymphovascular invasion
   Present 9
   Absent 15
Myometrial invasion
   < 1/2 10
   > 1/2 14
Lymph node surgery
   Pelvic lymph node dissection 10
   Pelvic and para-aortic lymph      
   node dissection 14
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An important issue in the SLN mapping of endometrial cancer 
is the injection site of the mapping material. We used cervical 
injection technique which is much easier than the fundal or 
sub-endometrial injections. High detection rate and sensitivity 
of our study was in accordance to other studies used cervical 
injection [19, 26]. Cervical injection is associated with extremely 
low para-aortic lymphatic drainage and some groups argue 
against this technique due to this fact. For example Solima et 
al. reported that 56% of their patients had para-aortic SLNs us-
ing sub-endometrial injection of the radiotracer [27]. However, 
frequency of isolated para-aortic without pelvic lymph node 
involvement in endometrial cancer patients is reported to be 
low. This was only 2% in Abu-Rustam et al. study [28]. We didn’t 
have any para-aortic node involvement in the patients underwent 
para-aortic lymph node dissection.
False negative rate is the most important outcome measure in 
all SLN mapping studies. Two recent systematic reviews evaluated 
the sentinel node concept in endometrial cancer and showed sen-
sitivity about 90% or more [23, 29]. We didn’t have any false nega-
tive results in our study either, as all 3 patients with involved pelvic 
nodes had positive SLNs too. However, the frozen section accuracy 
was lower with 1 (33%) false negative results. This false negative 
case occurred in the beginning of our study and can be attributed 
to the learning curve effect. This finding underscores the importance 
of expert pathologist in the evaluation of SLNs. The discrepan-
cies between frozen section and permanent H&E evaluation are not 
unknown in the literature [30], and can reach as high as 27% [27]. 
In the most recent study, Ballester et al. reported 56.3% sensitivity 
for intra-operative diagnostic methods [31]. For introduction of SLN 
mapping to any gynecological oncology center, this finding should 
be taken into account [32, 33].
Another important issue in the sentinel node mapping of midline 
tumors is the side of sentinel node identification [34, 35]. As midline 
tumors, lymphatic flow of the endometrial cancer should be bilateral 
in the pelvic area, however not all patients have bilateral lymphatic 
drainage during surgery. For example in our study, bilateral drain-
age could be detected in 16 out of 24 patients. 
Bilateral drainage in midline tumors (including endometrial 
cancer) is very important. In case of sentinel node detection failure 
on one side, possibility of pathological lymph node involvement on 
the detection failure side should be considered. In other words, 
Table 2. Anatomical distribution of the SLNs
Anatomic sites of SLN Number of SLNs
External iliac
   Right 12
   Left 7
Internal iliac
   Right 16
   Left 13
Obturator
   Right 26
   Left 15
Common iliac
   Right 5
   Left 1
out of 42 endometrial cancer patients. Intraoperative localization of the 
SLN was successful in 36 patients [14]. Niikura et al. also reported the 
same findings as lymphoscintigraphic SLN detection was 68% despite 
82% detection rate at surgery [15]. The above-mentioned findings can 
be due to proximity of injection site to the lymphatic basin which can 
mask the sentinel nodes on lymphoscintigraphy images [16, 17]. 
This problem can be overcome by SPECT/CT to some extent [18–20]. 
By improving the localization ability of the nuclear medicine imaging, 
SPECT/CT can contribute a lot to the sentinel node mapping of gyneco-
logical cancers. Lymphatic flow to the unusual anatomical sites can 
be also detected by SPECT/CT. It seems that SPECT/CT is becoming 
an integral part of sentinel node mapping in surgical oncology. 
The mapping method was highly related to SLN detection rate 
in our study, as the majority of harvested SLNs were detected by 
radiotracer and contribution of blue dye was minimal. The blue 
only SLNs were found during surgery of a patient without gamma 
probe at hand. Several other reports also supported our find-
ings as detection rate using radiotracer or combined radiotracer 
and blue dye was higher than blue dye alone [21–24]. Considering 
the potential risks of blue dye injections (such as life threatening 
anaphylaxis reactions), radiotracer alone may be sufficient for SLN 
mapping in endometrial cancer [25]. 
Figure 1. Anterior-Posterior lymphoscintigraphy images of a patient after cervical injection of the radiotracer. The sentinel nodes are shown in open 
arrows. At surgery two hot/blue external iliac nodes on the right side and one hot internal iliac node on the left side were detected
Nuclear Medicine Review 2014, Vol. 17, No. 2
www.nmr.viamedica.pl58
Original
each patient is considered as two separate units and decision to 
continue to regional lymphadenectomy should be based on the 
pathological condition of sentinel nodes of each side separately. 
This strategy has proven to decrease the false negative rate of 
sentinel node mapping in midline tumors [36]. Our study had rela-
tively low sample size and the effect of unilateral drainage on the 
accuracy of sentinel node mapping was not apparent. 
Conclusion
Lymphatic mapping and sentinel node biopsy is feasible and 
accurate in endometrial cancer patients using combined radiotracer 
and blue dye methods. Frozen section accuracy was lower and 
underscores the importance of expert pathologists for SLN map-
ping technique.
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